You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
阿斯利康上季疫苗銷售增至近9億美元 推遲向美國申請緊急使用
阿思達克 07-29 15:41
英國藥廠阿斯利康(AZN.US)第二季盈利下跌25%至5.5億美元,核心每股盈利爲0.9美元,不及市場預期。按固定匯率計算,第二季收入增長25%至82.2億美元,優於市場預期的75.8億美元。

季內新冠疫苗銷售額按季增長逾兩倍至8.94億美元,不過公司將推遲至下半年向美國當局申請批準使用疫苗。

阿斯利康近期完成收購稀有藥物業務Alexion,因此更新業績預測。在剔除疫苗銷售後,預計今年收入將增長至少20%,核心每股盈利爲5.05至5.4美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account